| Drug target prioritization by perturbed gene expression and network information Z Isik, C Baldow, CV Cannistraci, M Schroeder Scientific reports 5 (1), 17417, 2015 | 148 | 2015 |
| Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data AC Fassoni, C Baldow, I Roeder, I Glauche Haematologica 103 (11), 1825, 2018 | 72 | 2018 |
| Model-based inference and classification of immunologic control mechanisms from TKI cessation and dose reduction in patients with CML T Hähnel, C Baldow, J Guilhot, F Guilhot, S Saussele, S Mustjoki, S Jilg, ... Cancer research 80 (11), 2394-2406, 2020 | 32 | 2020 |
| Quantitative prediction of long-term molecular response in TKI-treated CML–Lessons from an imatinib versus dasatinib comparison I Glauche, M Kuhn, C Baldow, P Schulze, T Rothe, H Liebscher, A Roy, ... Scientific Reports 8 (1), 12330, 2018 | 25 | 2018 |
| Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology K Hoffmann, K Cazemier, C Baldow, S Schuster, Y Kheifetz, S Schirm, ... BMC medical informatics and decision making 20, 1-12, 2020 | 14 | 2020 |
| Model based analysis of clonal developments allows for early detection of monoclonal conversion and leukemia C Baldow, L Thielecke, I Glauche PloS one 11 (10), e0165129, 2016 | 13 | 2016 |
| Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation E Karg, C Baldow, T Zerjatke, RE Clark, I Roeder, AC Fassoni, I Glauche Frontiers in Oncology 12, 1028871, 2022 | 7 | 2022 |
| MAGPIE: Simplifying access and execution of computational models in the life sciences C Baldow, S Salentin, M Schroeder, I Roeder, I Glauche PLoS computational biology 13 (12), e1005898, 2017 | 6 | 2017 |
| HydraSAT 2009.3 solver description C Baldow, F Gräter, S Hölldobler, N Manthey, M Seelemann, P Steinke, ... SAT 2009 competitive events booklet: preliminary version, 15, 2009 | 5 | 2009 |
| Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy R Proschmann, C Baldow, T Rothe, M Suttorp, C Thiede, JT Tauer, ... haematologica 102 (2), e39, 2017 | 4 | 2017 |
| Clonal reconstruction from co-occurrence of vector integration sites accurately quantifies expanding clones in vivo S Wagner, C Baldow, A Calabria, L Rudilosso, P Gallina, E Montini, ... Nature Communications 13 (1), 3712, 2022 | 3 | 2022 |
| Drug target prioritization by perturbed gene expression and network information. Sci Rep. 2015; 5: 17417 Z Isik, C Baldow, CV Cannistraci, M Schroeder | 3 | |
| How to predict relapse in leukemia using time series data: A comparative in silico study H Hoffmann, C Baldow, T Zerjatke, A Gottschalk, S Wagner, E Karg, ... Plos one 16 (11), e0256585, 2021 | 2 | 2021 |
| Inferring immunological control mechanisms from TKI dose alterations in CML patients T Hähnel, C Baldow, AC Fassoni, J Guilhot, F Guilhot, S Saussele, ... bioRxiv, 722546, 2019 | 2 | 2019 |
| Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients–a Comparison of Imatinib and Dasatinib First-Line Therapy I Glauche, C Baldow, S Fröhlich, P Schulze, A Roy, M Subar, X Wang, ... Blood 124 (21), 4562, 2014 | 2 | 2014 |
| A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML I Glauche, H Liebscher, C Baldow, M Kuhn, P Schulze, T Haehnel, ... Blood 128 (22), 3099, 2016 | 1 | 2016 |
| P691: MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION E Karg, C Baldow, T Zerjatke, RE Clark, I Roeder, AC Fassoni, I Glauche HemaSphere 6, 586-587, 2022 | | 2022 |
| 3090–CLONAL RECONSTRUCTION FROM CO-OCCURRENCE OF VECTOR INTEGRATION SITES ALLOWS ACCURATE QUANTIFICATION OF EXPANDING CLONES IN VIVO I Glauche, S Wagner, C Baldow, A Calabria, L Rudilosso, P Gallina, ... Experimental Hematology 111, S89-S90, 2022 | | 2022 |
| Mathematical modelling of megakaryopoiesis in Mpl-deficient and continuously thrombopoietin-stimulated mice points to an unknown control mechanism HH Diebner, A Gottschalk, C Baldow, M Klose, I Glauche bioRxiv, 2020.05. 29.123489, 2020 | | 2020 |
| A mathematical modeling approach towards immunological control of minimal residual disease in CML patients I Glauche, A Fassoni, T Haehnel, C Baldow, I Roeder Experimental Hematology 53, S103, 2017 | | 2017 |
Ingo RoederFaculty of Medicine, TU Dresden在 tu-dresden.de 的电子邮件经过验证
